Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Cholangiocarcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2032

Cholangiocarcinoma Market is currently driven by factors such as a rising geriatric population, increasing number of patients with liver disease, a large smoking population, growing number of patients with diabetes, and rising safety and efficacy of current and emerging therapies, etc. Furthermore, the introduction of technologically advanced diagnostics that assist in monitoring tumour progression, assessing therapeutic response and clinical prognosis, and detecting recurrent tumours is further creating a positive outlook for the market.

Cholangiocarcinoma is a type of cancer involving the mutation of epithelial cells in the bile ducts. Some of the common factors responsible for the disease development include prolonged inflammation in the liver, biliary stones, abnormalities in the bile duct such as cysts, infection caused due to liver flukes parasite, and exposure to harmful chemicals and toxins. It occurs mostly in people over 65 years, though it may occur at any age. Cholangiocarcinoma is also slightly more common in men compared to women. The indication usually does not cause symptoms till it reaches an advanced stage and has spread to other organs and tissues. Few patients may, however, experience early symptoms. These may involve the yellowing of the skin and the whites of the eyes, itchiness of skin, light-colored stool, pain/bloating in the stomach, nausea and vomiting, loss of appetite/unexplained weight loss, fever, and fatigue.

IMARC Group’s new report "Cholangiocarcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast" provides an exhaustive analysis of the Cholangiocarcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The report provides an in-depth understanding of current and future landscape of the Cholangiocarcinoma market. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Cholangiocarcinoma across the seven major markets. According to the report, among the seven major markets, the United States has the largest patient pool for Cholangiocarcinoma and also represents the largest market for Cholangiocarcinoma treatment. Furthermore, the current Cholangiocarcinoma treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Cholangiocarcinoma market in any manner.

Time Period of the Study

  • Base Year: 2021
  • Historical Period: 2017-2021
  • Market Forecast: 2022-2032
     

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, Current and Future Epidemiology Scenario
  • Historical, Current and Future Performance of the Cholangiocarcinoma Market
  • Historical, Current and Future Performance of Various Therapeutic Categories in the Cholangiocarcinoma Market
  • Sales of Various Drugs Across the Cholangiocarcinoma Market
  • Reimbursement Scenario in the Cholangiocarcinoma Market
     

Cholangiocarcinoma: In-Market and Pipeline Drugs

This report also provides a detailed analysis of the current Cholangiocarcinoma marketed drugs and late-stage pipeline drugs.

  • In-Market Cholangiocarcinoma Drugs
    • Drug Overview
    • Mechanism of Action
    • Regulatory Status
    • Clinical Trial Results
    • Drug Uptake and Market Performance
  • Late-Stage Pipeline Cholangiocarcinoma Drugs
    • Drug Overview
    • Mechanism of Action
    • Regulatory Status
    • Clinical Trial Results
    • Regulatory Status
       

Key Questions Answered in this Report

Market Insights

  • How has the Cholangiocarcinoma market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2021 and how are they expected to be in 2032?
  • What was the country-wise size of the Cholangiocarcinoma market across the seven major markets in 2021 and how will it look like in 2032?
  • What is the growth rate of the Cholangiocarcinoma market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the Cholangiocarcinoma market?

 

Epidemiology Insights

  • What is the size of the Cholangiocarcinoma patient pool (2017-2021) across the seven major markets?
  • What would be the forecasted patient pool (2022-2032) of Cholangiocarcinoma across the seven major markets?
  • What are the key factors driving the epidemiological trend of Cholangiocarcinoma?
  • What will be the growth rate of Cholangiocarcinoma patients across the seven major markets?

 

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed Cholangiocarcinoma drugs and what are their market performance?
  • What are the key pipeline Cholangiocarcinoma drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed Cholangiocarcinoma drugs and what are their efficacies?
  • How safe are the late-stage pipeline Cholangiocarcinoma drugs and what are their efficacies?
  • What are the current treatment guidelines for Cholangiocarcinoma drugs across the seven major markets?
  • Who are the key companies in the Cholangiocarcinoma market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Cholangiocarcinoma market?

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Cholangiocarcinoma - Introduction
4.1 Overview
4.2 Epidemiology (2017-2021) and Forecast (2022-2032)
4.3 Market Overview (2017-2021) and Forecast (2022-2032)
4.4 Competitive Intelligence

5 Cholangiocarcinoma - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Cholangiocarcinoma - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2017-2021)
7.2.2 Epidemiology Forecast (2022-2032)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2017-2021)
7.3.2 Epidemiology Forecast (2022-2032)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2017-2021)
7.4.2 Epidemiology Forecast (2022-2032)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2017-2021)
7.5.2 Epidemiology Forecast (2022-2032)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2017-2021)
7.6.2 Epidemiology Forecast (2022-2032)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2017-2021)
7.7.2 Epidemiology Forecast (2022-2032)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2017-2021)
7.8.2 Epidemiology Forecast (2022-2032)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2017-2021)
7.9.2 Epidemiology Forecast (2022-2032)

8 Cholangiocarcinoma - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Cholangiocarcinoma Guidelines, Management and Treatment
8.2 Cholangiocarcinoma Treatment Algorithm

9 Cholangiocarcinoma - Unmet Needs

10 Cholangiocarcinoma - Key Endpoints of Treatment

11 Cholangiocarcinoma - Marketed Products
11.1 List of Cholangiocarcinoma Marketed Drugs Across the Top 7 Markets
11.1.1    Drug Name - Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Drug and company names have not been provided here as this is a sample TOC. Complete list to be provided in the final report.

12 Cholangiocarcinoma - Pipeline Drugs
12.1 List of Cholangiocarcinoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name - Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Drug and company names have not been provided here as this is a sample TOC. Complete list to be provided in the final report.

13. Cholangiocarcinoma - Attribute Analysis of Key Marketed and Pipeline Drugs

14 Cholangiocarcinoma - Market Scenario
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1    Cholangiocarcinoma - Market Size
14.2.1.1 Market Size (2017-2021)
14.2.1.2 Market Forecast (2022-2032)
14.2.2    Cholangiocarcinoma - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2017-2021)
14.2.2.2 Market Forecast by Therapies (2022-2032
14.3 Market Scenario - United States
14.3.1    Cholangiocarcinoma - Market Size
14.3.1.1 Market Size (2017-2021)
14.3.1.2 Market Forecast (2022-2032)
14.3.2    Cholangiocarcinoma - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2017-2021)
14.3.2.2 Market Forecast by Therapies (2022-2032)
14.3.3    Cholangiocarcinoma - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1    Cholangiocarcinoma - Market Size
14.4.1.1 Market Size (2017-2021)
14.4.1.2 Market Forecast (2022-2032)
14.4.2    Cholangiocarcinoma - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2017-2021)
14.4.2.2 Market Forecast by Therapies (2022-2032)
14.4.3    Cholangiocarcinoma - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1    Cholangiocarcinoma - Market Size
14.5.1.1 Market Size (2017-2021)
14.5.1.2 Market Forecast (2022-2032)
14.5.2    Cholangiocarcinoma - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2017-2021)
14.5.2.2 Market Forecast by Therapies (2022-2032)
14.5.3    Cholangiocarcinoma - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1    Cholangiocarcinoma - Market Size
14.6.1.1 Market Size (2017-2021)
14.6.1.2 Market Forecast (2022-2032)
14.6.2    Cholangiocarcinoma - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2017-2021)
14.6.2.2 Market Forecast by Therapies (2022-2032)
14.6.3    Cholangiocarcinoma - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1    Cholangiocarcinoma - Market Size
14.7.1.1 Market Size (2017-2021)
14.7.1.2 Market Forecast (2022-2032)
14.7.2    Cholangiocarcinoma - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2017-2021)
14.7.2.2 Market Forecast by Therapies (2022-2032)
14.7.3    Cholangiocarcinoma - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1    Cholangiocarcinoma - Market Size
14.8.1.1 Market Size (2017-2021)
14.8.1.2 Market Forecast (2022-2032)
14.8.2    Cholangiocarcinoma - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2017-2021)
14.8.2.2 Market Forecast by Therapies (2022-2032)
14.8.3    Cholangiocarcinoma - Access and Reimbursement Overview
14.9   Market Scenario - Japan
14.9.1    Cholangiocarcinoma  - Market Size
14.9.1.1 Market Size (2017-2021)
14.9.1.2 Market Forecast (2022-2032)
14.9.2    Cholangiocarcinoma - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2017-2021)
14.9.2.2 Market Forecast by Therapies (2022-2032)
14.9.3    Cholangiocarcinoma - Access and Reimbursement Overview

15 Cholangiocarcinoma - Recent Events and Inputs From Key Opinion Leaders

16 Cholangiocarcinoma Market - SWOT Analysis
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats     

17 Appendix


Note: We value your privacy and will never rent or sell your email address. Privacy policy

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 4499

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links

4